Abstract: A method for extracting and identifying a polysaccharide from a complex sample. The method includes: subjecting a complex sample to be treated to sterilization and enzyme deactivation to obtain a system, and subjecting the system to solid-liquid separation to obtain a sterilization and enzyme deactivation-treated solution; deproteinizing the sterilization and enzyme deactivation-treated solution to obtain a deproteinized solution; purifying the deproteinized solution by using a hydrophilic lipophilic balance-solid phase extraction (HLB-SPE) cartridge to obtain a purified solution; subjecting the purified solution to alcohol precipitation to obtain the polysaccharide; and subjecting the polysaccharide to methylation, glycoside residue derivatization and liquid chromatography-mass spectrometry (LC-MS) analysis in sequence.

Abstract: The invention relates to a method for producing cationized cellulose. The method comprises at least preparing a slurry of a cellulosic starting material in an alkaline liquid medium which comprises an organic liquid and performing mercerization of the slurry. The concentration of the cellulosic starting material in the slurry is at least 20 weight-%, calculated as dry from total weight of the liquid medium and the cellulosic starting material. A cationizing agent is added to the slurry after the mercerization step at a cationization temperature, which is less than the boiling point of the alkaline liquid medium, and the cellulose in the slurry is allowed to react with the cationizing agent, preferably under inert atmosphere and a cationized cellulose product is obtained.

Abstract: In order to provide a safe food-derived ingredient that reduces side effects of a cancer chemotherapeutic agent, and particularly to provide a food, a food ingredient (supplement), and a drug that reduce lethal toxic effects of a chemotherapeutic agent, a cancer chemotherapy supporting agent, a food, and a drug according to the present invention are supporting agents for a cancer chemotherapy in which streptozotocin etc., is administered, contain a lipopolysaccharide constituted of Pantoea bacteria LPS etc. as an active ingredient, and are orally administered.

Abstract: A lactic acid adsorbent includes a layered double hydroxide that contains multiple metal hydroxide layers and also contains anions and water molecules held between the metal hydroxide layers. The anions include (i) an amino acid such as glutamine, (ii) a dipeptide constituted by one or two kinds of amino acids such as glutamine, (iii) a vitamin such as ascorbic acid 2-phosphate, (iv) a pH buffer such as MES, (v) a glucose metabolite such as pyruvic acid, or (vi) inorganic ions selected from a group including NO3? and Cl?.

Abstract: The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical compositions containing one or more NAD+ modulating compounds as a first ingredient in combination with one or more active pharmaceutical ingredients. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and/or improving cell and tissue survival.

Abstract: The present invention provides compositions, systems, kits, and methods for treating a subject with an RNA virus infection (e.g., SARS-COV-2) by administering or providing a composition comprising a cytidine deaminase inhibitor (e.g., tetrahy-drouridine or cedazuridine).

Abstract: The present invention relates to methods for purifying nucleic acids. In particular, the present invention relates to methods for purifying carbohydrate-conjugated oligonucleotides using a mixed-mode stationary phase and a mobile phase comprising a dual salt/organic solvent gradient. Methods for purifying carbohydrate-conjugated oligonucleotides using an anion exchange stationary phase and a mobile phase comprising a dual pH/salt gradient are also described.

Abstract: A major hurdle in the treatment of cancer is chemoresistance induced under hypoxia that is characteristic of tumor microenvironment. Triptolide, a potent inhibitor of eukaryotic transcription, possesses potent antitumor activity. However, its clinical potential has been limited by toxicity and water solubility. To address those limitations of triptolide, the present disclosure designed and synthesized glucose-triptolide conjugates (glutriptolides) and demonstrated their antitumor activity in vitro and in vivo. The glutriptolides disclosed herein possess improved stability in human serum, greater selectivity towards cancer over normal cells and increased potency against cancer cells. Importantly, the glutriptolides are more potent against cancer cells under hypoxic conditions in contrast to existing cytotoxic drugs. These glutriptolides also exhibit sustained antitumor activity, prolonging survival in a prostate cancer metastasis animal model.

Abstract: The present disclosure provides methods for synthesizing oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage. In certain embodiments, the present disclosure provides oxidation reagents that produce low amounts of unwanted phosphate diester impurities in oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage.

Abstract: The present disclosure provides linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

Abstract: The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents a hydrogen atom and the like, W represents an oxygen atom and the like, and X represents a C1-6 alkyl group and the like.

Abstract: A material with a scaffold comprising a series of at least partially spaced fibers and gas vesicles locates between fibers. The gas vesicles comprise external anchoring modules that are effective to anchor the gas vesicles to the fibers.

Abstract: The present invention provides a hyaluronic acid derivative having a steryl group introduced therein, wherein a ratio Mw/Mn of a weight-average molecular weight Mw to a number-average molecular weight Mn of the hyaluronic acid derivative is 1.11 or more and 10.0 or less.

Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a far-red dye probe and a non-linear surfactant or foamban. Also disclosed are related methods for preparing a lyophilized far-red dye probe formulation as well as related kits and diagnostic products.

Abstract: The invention relates to a new protein hydrogel created on the basis of low-concentrated components: reagents A and B, the method of hydrogel preparation and its use.

Abstract: The present invention relates to a method of preparation of Glycolipid carboxylic acids of Formula I by selective hydrolysis of corresponding esters by enzymes. The method provides preparation of compounds of Formula I in high yield by an environmentally benign, robust, economical, simple and convenient method.

Abstract: The invention is in the field of vaccines and relates to oligomers having a selected degree of polymerization, obtained by connecting together a number of carbocyclic repeating units, and to conjugated derivatives thereof. The oligomers and conjugated derivatives thereof of the invention also have a selected degree of acetylation. The derivatives of the invention are useful for the preparation of immunogenic compositions, e.g. in the form of a vaccine.

Abstract: Provided herein are compositions, devices, systems and methods for DNA oligomer synthesis. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.). The compositions, devices, systems and methods described herein provide improved synthesis, storage, density, and retrieval of biomolecule-based information.

Abstract: Provided is a method for collecting RNA contained in skin surface lipids (SSL). A method for preparing SSL-derived RNA. In this method, an aqueous solution containing RNA prepared from SSL of a subject is mixed with a water-soluble organic solvent, and the resulting mixture is allowed to contact with a solid phase material to separate RNA. By adjusting the concentration of the water-soluble organic solvent in the mixture, the yield of RNA improves.

Abstract: The present disclosure relates to compounds that inhibit SETBP1 or XP01 activities. Also disclosed are methods of using such compounds to increase the expression of embryonic and fetal hemoglobin molecules, and to treat sickle cell disease and ?-thalassemia. The present invention relates to unexpected findings that transcription factor SETBP1 regulates embryonic and fetal hemoglobin repression, and inhibition of SETBP1 can induce the expression of embryonic and fetal hemoglobins.